Clinical Trial Supply Management: Beyond the IRT

At a glance

• Clinical trial supply management is the discipline of getting the right investigational product to the right participant at the right time, without stockouts and without wasteful overage.
• It runs on top of the IRT/RTSM engine, not inside it. The system automates randomization-driven dispensing and inventory; the human supply lead owns the forecasting assumptions and the depot strategy.
• Demand forecasting is where waste is won or lost. The variables that matter are the enrollment curve, screen-fail rate, dropout, dosing schedule, and manufacturing/release lead time.
• Drug accountability and returns/destruction (DARM) are a GCP obligation: you must be able to document the identity, shipment, receipt, return, and destruction of the IMP.
• A small team can run lean. The question is whether your trial’s complexity justifies dedicated supply software or whether disciplined process plus your IRT can cover it.

Vendor pages on this topic tend to conflate “supply management” with “buy our RTSM” and skip the operational layer a sponsor team actually owns: the forecasting inputs, the depot-and-resupply logic, and the drug-accountability workflow. They also blur the line between what the IRT automates and what the human supply lead still decides. This guide gives you the operating model: the end-to-end IMP journey, the split between supply management and the IRT, the forecasting variables that drive overage, the accountability and returns workflow, and a sober view of whether you need dedicated software. It does not teach randomization algorithms or IRT build mechanics, and it is not an RTSM product comparison; those are separate topics.

What clinical trial supply management actually is

Supply management is the end-to-end handling of the investigational medicinal product (IMP): manufacture, release, distribution to depots, shipment to sites, dispensing to participants, and return or destruction at the end. GCP makes IMP handling a named responsibility. ICH E6(R3) principle 11 states that investigational products should be manufactured to applicable GMP, that measures should ensure the IMP provided to participants retains its quality, that it be used in accordance with the protocol, and that appropriate processes be implemented for handling, shipping, storage, dispensing, returning, and destroying or disposing of the IMP (ICH E6(R3) §II, principle 11). That sentence is the whole supply lifecycle in regulatory form.

The framing that helps a small team is this: supply management is a forecasting-and-accountability discipline. Forecasting keeps product available without waste; accountability proves what happened to every unit.

Supply management vs RTSM/IRT, who does what

The most useful distinction is between the engine and the discipline that rides on it.

What the IRT/RTSM engine automates

The interactive response technology (IRT), also called RTSM, automates the mechanical parts: randomization-driven dispensing, real-time inventory visibility, and automated resupply triggers. It is the system of record for which unit went to which participant and what stock each site holds.

What the human supply lead still owns

The IRT does not decide your assumptions. The supply lead owns the forecasting inputs, the depot strategy, and the overage tolerance, the judgment calls the engine then executes. GCP keeps the responsibility with the sponsor: the sponsor must maintain records documenting the identity, shipment, receipt, return, and destruction or alternative disposition of the IMP, maintain processes for retrieving and for disposing of unused product, and ensure the product is stable over the period of use and used within its shelf life (ICH E6(R3) §3.15). The IRT helps you execute those duties; it does not absolve you of them.

Demand forecasting: the variables that drive overage and waste

Forecasting is where supply budgets are made or blown. The variables that actually move the numbers:

• Enrollment curve: how fast participants come in, by site and region.
• Screen-fail rate: how many screened participants never randomize (and still may consume screening supply).
• Dropout: how many randomized participants leave, freeing or stranding supply.
• Dosing schedule: units per participant per visit over the treatment period.
• Manufacturing and QP/release lead time: how long it takes to make and release more, which sets how far ahead you must forecast.

A worked example

Suppose you plan 100 randomized participants, a 30% screen-fail rate (so ~143 screened), a chronic daily oral dose of one unit, 24 weeks of treatment, and a 15% dropout. Naive demand is 100 x 168 days = 16,800 units. Dropout reduces realized consumption but not what you must pre-position, and screen failures plus dispensing-pack rounding add more. With a manufacturing lead time of several months, you cannot resupply reactively, so you hold an overage buffer (commonly a meaningful percentage on top of forecast) to absorb faster-than-planned enrollment. The point of the example is that overage is a deliberate, forecast-driven decision, not a guess. Forecasting models (moving average, Croston’s method for intermittent demand, among others) are named industry techniques you apply to these inputs.

Depot and distribution strategy

A depot is a regional warehouse that supplies sites. The decision is single versus multiple depots, driven by geography, import/export and customs, and cold-chain needs. More depots reduce shipping time and customs risk but increase the inventory you must hold and reconcile. Because the IMP must retain its quality through distribution (ICH E6(R3) §II, principle 11), cold-chain integrity and storage conditions are part of the depot decision, not an afterthought.

Resupply logic and trigger thresholds

Resupply is rule-driven: when a site’s usable stock falls below a threshold (set against expected consumption and shipping lead time), the IRT triggers a shipment. A simple, sound rule is to resupply when on-hand stock would not cover expected demand through the next lead-time window plus a safety margin. The supply lead sets those thresholds; the IRT enforces them.

Drug accountability, returns and destruction (DARM)

Accountability is the audit trail of the physical product, and it is a GCP requirement, not bookkeeping nicety. You must be able to account for every unit: dispensed, returned, or destroyed. ICH E6(R3) requires the sponsor to maintain records of the identity, shipment, receipt, return, and destruction or alternative disposition of the IMP, and to maintain processes for retrieving product (for example, recalls or expired-product reclaim) and for disposing of unused product (ICH E6(R3) §3.15).

From paper logs to electronic accountability

Many teams start with paper accountability logs and move to electronic systems. The moment accountability goes electronic, it becomes a computerised system under EU Annex 11, which expects such systems to be validated, to restrict access to authorized persons, and to maintain an audit trail of changes and deletions with the reason documented (EU Annex 11, Principle, §9, §12). For critical data entered manually, Annex 11 also expects an additional accuracy check, by a second operator or validated electronic means (EU Annex 11, §6). So an electronic accountability tool is not just a spreadsheet with extra columns; it carries the same controls as any GMP computerised system.

Reconciliation and closeout

At closeout, supply is reconciled: shipped equals dispensed plus returned plus destroyed plus remaining, with discrepancies investigated. This reconciliation is what an inspector checks, and it is only possible if the records were kept contemporaneously throughout (ICH E6(R3) §3.15).

Two checklists you can reuse

Two short, reusable artifacts cover most of what a lean team needs. The first is the forecasting-input checklist: the variables you must pin down before you can size supply at all.

FORECASTING INPUTS
[ ] Enrollment curve (rate by site/region, ramp-up)
[ ] Screen-fail rate (and screening-supply consumption)
[ ] Dropout / discontinuation rate
[ ] Dosing schedule (units per participant per visit; treatment duration)
[ ] Manufacturing + QP/release lead time
[ ] Overage tolerance (buffer % above forecast)
[ ] Number and location of depots (shipping lead time per site)

The second is the drug-accountability and reconciliation checklist, which maps directly to the GCP records the sponsor must maintain for the identity, shipment, receipt, return, and destruction of the IMP (ICH E6(R3) §3.15).

DRUG ACCOUNTABILITY / RECONCILIATION
[ ] Receipt logged at site (quantity, batch, condition, date)
[ ] Dispensing recorded per participant
[ ] Returns recorded (used/unused) per participant
[ ] Temperature excursions assessed and dispositioned
[ ] Expiry/shelf-life checked; expired stock quarantined
[ ] Destruction or return documented with authorisation
[ ] Closeout reconciliation: shipped = dispensed + returned + destroyed + remaining

Keep both current as the trial runs; reconstructing them at closeout is exactly the scramble that produces discrepancies an inspector will probe.

Expiry dating and temperature excursion handling

Two recurring operational risks: expiry and temperature. The IMP must be used within its shelf life and remain stable over the period of use (ICH E6(R3) §3.15), so expiry management (and re-labeling/extension where supported by stability data) is an active task, not a set-and-forget. Temperature excursions during shipping or storage threaten the principle 11 requirement that the IMP retain its quality (ICH E6(R3) §II, principle 11); a defined excursion process (quarantine, assess against stability data, release or destroy) is essential, and where excursion data is captured electronically, Annex 11’s data-integrity and audit-trail controls apply (EU Annex 11, §9).

Do small teams need supply software? (a sober buyer’s view)

Not always on day one. A small, single-region trial with simple dosing can often be run with a capable IRT plus disciplined forecasting and accountability process. Dedicated supply-management software earns its place when complexity rises: multiple depots, cold chain, complex dosing, or many sites across regions. Whatever you use, the regulatory floor is unchanged: you must be able to forecast responsibly, keep the IMP within quality and shelf life, and account for every unit (ICH E6(R3) §II principle 11, §3.15), and any electronic tool must carry Annex 11 controls.

A note on boundaries: TrialTrack handles clinical project management, not drug supply or IRT. It does not manage IMP inventory, randomization, or accountability; it tracks the operational project around the trial. For supply itself, an IRT/RTSM and, if needed, supply software are the relevant tools.

The bottom line

Treat clinical trial supply management as forecasting plus accountability layered on the IRT. Let the IRT automate dispensing, inventory, and resupply triggers, but own the assumptions yourself: the enrollment, screen-fail, dropout, dosing, and lead-time variables that drive overage, and the depot strategy. Keep the IMP within quality and shelf life, run a defined excursion process, and account for every unit from shipment to destruction, because GCP requires it and any electronic tool you use must meet Annex 11’s controls. Do that, and a lean team can avoid both stockouts and waste without an enterprise supply suite.

Sources

• ICH E6(R3) Good Clinical Practice
• EudraLex Volume 4, Annex 11: Computerised Systems